Dashboard
Manage Tickers

LPCN Lipocine Inc.

Nasdaq lipocine.com


$ 3.02 $ -0.09 (-2.89 %)    

Friday, 17-Oct-2025 15:49:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 3.02
$ 3.14
$ 2.90 x 40
$ 3.19 x 61
$ 2.98 - $ 3.14
$ 2.65 - $ 6.17
12,716
na
16.37M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-09-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-13-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-06-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-07-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-08-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-08-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
08/20/2025 13:11:10

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

correction-lipocine-q2-eps-041-misses-040-estimate-sales-622849k-beat-229000k-estimate
CORRECTION: Lipocine Q2 EPS $(0.41) Misses...
08/05/2025 14:11:02

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by...

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
06/27/2025 15:25:51

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

lipocine-doses-first-patient-in-phase-3-trial-of-lpcn-1154-in-postpartum-depression
Lipocine Doses First Patient In Phase 3 Tr...
06/26/2025 12:08:33

hc-wainwright--co-reiterates-buy-on-lipocine-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Lipo...
06/10/2025 11:00:38

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.

lipocine-says-licensing-partner-verity-pharma-files-new-drug-submission-for-tlando-in-canada
Lipocine Says Licensing Partner, Verity Ph...
06/09/2025 12:01:53

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually fo...

lipocine-shareholders-approved-amendment-to-cut-authorized-common-stock-from-200m-to-75m-shares-at-annual-meeting-held-on-june-4-2025
Lipocine Shareholders Approved Amendment t...
06/09/2025 11:46:06

lipocines-licensing-partner-verity-pharma-filed-a-new-drug-submission-for-tlando-in-canada-tlando-is-the-first-and-only-oral-testosterone-replacement-therapy-option-approved-by-fdathat-does-not-require-dose-titration
Lipocine's Licensing Partner, Verity Pharm...
06/09/2025 10:25:27

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually fo...

hc-wainwright--co-assumes-lipocine-at-buy-announces-price-target-of-8
HC Wainwright & Co. Assumes Lipocine at Bu...
05/29/2025 14:46:45

HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and announces Price Target of $8.

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
05/19/2025 12:09:34

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
05/12/2025 17:07:15

lipocine-q1-eps-035-beats-041-estimate-sales-9386k-miss-37000k-estimate
Lipocine Q1 EPS $(0.35) Beats $(0.41) Esti...
05/08/2025 12:10:05

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 1...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 21:06:18

lipocine-enters-into-license-and-supply-agreement-with-ach-laboratrios-farmacuitcos-sa-granting-exclusive-rights-to-market-tlando-in-brazil
Lipocine Enters Into License And Supply Ag...
05/06/2025 12:04:50

Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Ora...

lipocine-announces-initiation-of-a-phase-3-trial-for-lpcn-1154-which-is-in-development-for-treatment-of-postpartum-depression
Lipocine Announces Initiation Of A Phase 3...
03/26/2025 12:06:13

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective ora...

lipocine-fy24-sales-11198m-beat-10321m-estimate
Lipocine FY24 Sales $11.198M Beat $10.321M...
03/13/2025 12:09:37

lipocine-announces-revised-fda-guidance-for-lpcn-1154-requiring-efficacy-and-safety-study-for-postpartum-depression-nda-submission
Lipocine Announces Revised FDA Guidance Fo...
02/06/2025 13:04:27

fda-grants-fast-track-designation-to-lipocines-lpcn-1148-for-treating-sarcopenia-in-patients-with-decompensated-cirrhosis-targeting-first-in-class-status-with-novel-mechanism-of-action
FDA Grants Fast Track Designation To Lipoc...
12/17/2024 13:02:18

lipocine-announces-the-publication-and-discussion-of-a-manuscript-oral-lpcn-1148-improves-sarcopenia-and-hepatic-encephalopathy-in-male-patients-with-cirrhosis-a-randomized-placebo-controlled-phase-2-trial-in-the-journal-hepatology-and-discussion-at-the-liver-meeting-2024-editors-cut
Lipocine Announces The Publication And Dis...
11/18/2024 13:14:20

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics...

lipocine-q3-eps-044-beats-048-estimate
Lipocine Q3 EPS $(0.44) Beats $(0.48) Esti...
11/07/2024 13:09:27

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION